Bousman, C A

Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA schizophrenia DTI working group

Kelly, S., Jahanshad, N., Zalesky, A., Kochunov, P., Agartz, I., Alloza, C., Andreassen, O. A., Arango, C., Banaj, N., Bouix, S., et al. (2018) · Molecular Psychiatry

Schizophrenia research and treatmentAdvanced Neuroimaging Techniques and Applications

Cited by 701

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 , CYP2C19 , CYP2B6 , SLC6A4 , and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants

Bousman, C. A., Stevenson, J. M., Ramsey, L. B., Sangkuhl, K., Hicks, J. K., Strawn, J. R., Singh, A. B., Ruaño, G., Mueller, D. J., Tsermpini, E. E., et al. (2023) · Clinical Pharmacology & Therapeutics

Pharmacogenetics and Drug MetabolismGenetic Associations and Epidemiology

Cited by 521

Accelerated Gray and White Matter Deterioration With Age in Schizophrenia

Cropley, V. L., Klauser, P., Lenroot, R. K., Bruggemann, J., Sundram, S., Bousman, C., Pereira, A., Di Biase, M. A., Weickert, T. W., Weickert, C. S., et al. (2017) · American Journal of Psychiatry

Schizophrenia research and treatmentMental Health and Psychiatry

Cited by 217

Effects of Clozapine Treatment on the Improvement of Substance Use Disorders Other than Nicotine in Individuals with Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis

Rafizadeh, R., Danilewitz, M., Bousman, C. A., Mathew, N., White, R. F., Bahji, A., Honer, W. G., & Schütz, C. G. (2023) · Journal of Psychopharmacology

Schizophrenia research and treatmentSubstance Abuse Treatment and Outcomes

Cited by 41

Effects of NRG1 and DAOA genetic variation on transition to psychosis in individuals at ultra-high risk for psychosis

Bousman, C. A., Yung, A. R., Pantelis, C., Ellis, J. A., Chavez, R. A., Nelson, B., Lin, A., Wood, S. J., Amminger, G. P., Velakoulis, D., et al. (2013) · Translational Psychiatry

Schizophrenia research and treatmentGenetic Associations and Epidemiology

Cited by 38

Moving pharmacoepigenetics tools for depression toward clinical use

Hack, L. M., Fries, G. R., Eyre, H. A., Bousman, C. A., Singh, A. B., Quevedo, J., John, V. P., Baune, B. T., & Dunlop, B. W. (2019) · Journal of Affective Disorders

Treatment of Major DepressionEpigenetics and DNA Methylation

Cited by 33

N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial

Sarris, J., Byrne, G., Castle, D., Bousman, C., Oliver, G., Cribb, L., Blair-West, S., Brakoulias, V., Camfield, D., Ee, C., et al. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry

Obsessive-Compulsive Spectrum DisordersAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 19